A Texas Senate committee on Wednesday unanimously approved a House-passed bill that would require the state to conduct a study into the therapeutic potential of psychedelics like psilocybin and MDMA.
Exploring the companies and themes that make up this emerging and exciting new sector
Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder
Cybin announces approval to enter its Phase IIa clinical study and defines the scope of the clinical trial.
A single dose of psilocybin has a lasting therapeutic effect on migraine headache, according to a new placebo-controlled study
Scientists have started to investigate whether psilocybin, the primary substance responsible for the psychedelic effects of “magic” mushrooms, could be helpful to those who suffer from migraine headache.
Canadians Are Not OK, 83% of Canadians Report One Or More Symptoms of Depression With Many Turning To Substances To Cope With Negative Emotions During COVID-19 Pandemic, According to Field Trip Health's First Annual "State of Mind" Survey
Over 80% of Canadians are showing symptoms of depression related to the COVID-19 pandemic, with over half of Canadians feeling "down, depressed or hopeless".
Novamind Opens Client Care Center to Support High Demand for Treatments
Novamind is adding a second Client Care Center as it expands its clinic network from four to eight locations.
FDA Endorses Psychedelics 'Guided Experience' Model
The FDA has approved the use of MDMA by therapists -- to better prepare them to administer MDMA-assisted psychotherapy.
Decriminalizing Psychedelic Drugs in California: As State Senate Considers Bill, Debate Continues
A bill to decriminalize psychedelic drugs is currently being considered by the California Legislature.
Psychedelic Drugs To The Rescue: Professional Sports Turn To Psychedelics
Traumatic Brain Injury is another major treatment market targeted by psychedelics R&D. TBIs are now a health crisis in many professional sports. Opportunity knocks.
Turn On, Tune In, Feel Better: The Rise of Psychedelic Therapy in Texas
On the day it opened in early May, Field Trip Health’s therapeutic facility in Houston’s uptown neighborhood looked a little like a high-end strip-mall spa. Dressed in a floral shirt, Matt Emmer, the company’s director of operations and business development, showed me the clinic’s amenities.
MindMed Announces 2021 Q1 Financial Results; Cash Balance of $160m USD ($194m CAD) to Execute on Diverse Clinical Pipeline
MindMed reports a net loss of CAD$14 million for Q1, with US$160 million in cash and a total cash burn for the quarter of CAD$10 million.
Numinus Wellness Announces Key Leadership Hires to Support Rapid Growth and Innovation
Numinus fills several key roles including a new Director of Mergers and Acquisitions and a new Chief Communications Officer.
COMPASS Pathways plc announces financial results and business highlights for the first quarter 2021
Compass Pathways highlights for Q1 include two new patents and reports its Phase IIb clinical trial is on track.